Partners
Join us in making early detection the global standard of care.
Be Part Of A Global Transformation
When you partner with Cizzle Bio, you’re helping lead a transformation in how cancer is detected and diagnosed. Together, we’re connecting the world to our patented CIZ1B and DEX-G2 biomarker blood tests—breakthrough technologies designed to identify lung and gastric cancers at their earliest, most treatable stages.
Cizzle Bio works closely with NCI-designated cancer centers, academic medical institutions, nonprofit organizations, and patient advocacy groups across the United States. Through these collaborations, we are advancing large-scale clinical validation studies to demonstrate the power of our tests in improving patient outcomes and reshaping the future of cancer care.
Current Clinical Initiatives
Our commitment to rigorous science is at the heart of every partnership.
Currently, an IRB-approved clinical validation study at Moffitt Cancer Center is underway, analyzing 250 patients with identified lung nodules. This retrospective study is generating critical insights into how the CIZ1B biomarker test can predict cancer risk—supporting both initial diagnosis and long-term patient monitoring.
Building on this momentum, additional clinical studies are being launched or under review at leading cancer centers, medical institutions, and health systems nationwide for both our CIZ1B and DEX-G2 biomarker blood tests:
Mays Cancer Center/UT Health San Antonio MD Anderson Cancer Center
Texas IPS/Methodist Health
Hoag Family Cancer Institute
City of Hope Comprehensive Cancer Center
UCLA Health
Duke Health
These studies are paving the way for broader clinical adoption, ensuring that more patients can benefit from the life-saving potential of early cancer detection.
Current Key Partners
We are proud to work alongside world-class research institutions and organizations that share our mission of advancing early cancer detection.
Cizzle Bio is actively building collaborations that accelerate innovation and expand access to early cancer detection. We welcome discussions with health systems, cancer centers, research institutions, and pharmaceutical and biotech companies who share our vision of making life-saving biomarker technologies available to more patients across the United States and around the world.
If you’re interested in exploring how a partnership with Cizzle Bio can bring breakthrough blood-based cancer tests to the patients who need them most, we invite you to connect with us.